ZPL-5212372

ZPL-5212372 (PF 5212372) is a cPLA2α inhibitor (IC50 = 7 nM) . ZPL-5212372 inhibits the release of prostaglandin D2 (PGD2), cysteyl leukotrienes, leukotriene B4, thromboxane A2, and PGD2 from human lung cells. ZPL-5212372 inhibits delayed bronchoconstriction and airway hyperresponsiveness in a sheep allergic inflammation model. ZPL-5212372 may be used in asthma research[1].

Product Specifications

CAS Number

[916136-25-9]

Product Name Alternative

PF 5212372

UNSPSC

12352005

Target

Leukotriene Receptor; Phospholipase; Prostaglandin Receptor

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Smiles

O=C(O)CCC1=CC=C(S(=O)(CCC2=C(CCNS(=O)(CC3=CC=CC=C3C(F)(F)F)=O)N(C(C4=CC=CC=C4)C5=CC=CC=C5)C6=C2C=C(Cl)C=C6)=O)C=C1

Molecular Formula

C42H38ClF3N2O6S2

Molecular Weight

823.34

References & Citations

[1]Hewson CA, et al. Preclinical evaluation of an inhibitor of cytosolic phospholipase A2α for the treatment of asthma. J Pharmacol Exp Ther. 2012 Mar;340 (3) :656-65.